Cross-sectional analysis and prospective observational study of sleep quality, lung function, ventilatory muscle strength, ventilatory patterns, autonomic nervous activity, disease severity, clinical status and quality of life in Myasthenia Gravis: a research protocol.
Oliveira, Ezequiel Fernandes; Nacif, Sergio Roberto; Fonsêca, Nina Teixeira; Santos, Israel Reis; Urbano, Jessica Julioti; Dias, Ismael Sousa; Almeida, Rafael Guia; Apostolico, Nadua; Ferraz, Leonardo Macário; Araújo, Ana Karina Fachini; Sampaio, Luciana Maria Malosá; Perez, Eduardo de Araujo; Leitão Filho, Fernando Sergio S.; Bosio, Paulo Cesar; Romano, Salvatore; Salvaggio, Adriana; Insalaco, Giuseppe; Braghiroli, Alberto; Oliveira, Claudia Santos; Cavalcanti, Rafael Limeira; Bulle, Acary Sousa; Oliveira, Luis Vicente Franco
Introduction: The presence of sleep disorders in Myasthenia gravis (MG) patients, can negatively affect the ventilation and the mechanics of breathing in patients with neuromuscular diseases. Some studies have shown a poor quality of sleep, excessive daytime sleepiness and the presence of sleep disordered breathing, while others did not observe a positive correlation. The aim of the study is to investigate sleep quality, lung function, ventilatory patterns, autonomic nervous activity, disease severity, clinical status and quality of life in clinically stable MG patients. Method: We propose a cross sectional analysis and prospective observational study of sleep quality, lung function, ventilatory patterns, autonomic nervous activity, disease severity, clinical status and quality of life in MG patients which will be conducted at the Sleep Laboratory of Nove de Julho University and the Neuromuscular Research Department of the Federal University of São Paulo. The design, conduct, and reporting of this study will follow the rules of The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement. The protocol will includes body weight; height; body mass index; circumferences of the neck, waist, and hip; heart and respiratory rates; Mallampati index; maximum ventilatory pressures; spirometry; and standard overnight polysomnography, as well as the administration of specific questionnaires addressing the risk of obstructive sleep apnoea, excessive daytime sleepiness and HRQoL. Moreover, specific questionnaires addressing sleep apnoea; excessive daytime sleepiness; symptoms of stress, depression, anxiety, disease severity, clinical status and quality of life will be administered. The 8 outcome variables which will be measured include subjective sleepiness Epworth Sleepiness Scale (ESS), risk of OSA through The Berlin Questionnaire, stress and its manifestations by The Inventory of Symptoms of Stress for Adults (LIPP), anxiety and depression by The Hospital Anxiety and Depression Scale (HAD), general quality of life questionnaire using The Short Form 36 (SF36) and specific outcome measure MGQOL 15, MG Composite Scale and The Quantitative Myasthenia Gravis Score. Discussion: This protocol expects to identify the presence and severity of sleep disorders, changes of autonomic nervous activity, HRQoL and consequently contribute to an earlier diagnosis, thus reducing the impact on quality of life of MG patients.
1. Christensen PB, Jensen TS, Tsiropoulos I, Sorensen T, Kjaer M, Hojer-Pedersen E, et al. Mortality and survivalin myasthenia gravis: A Danish population based study. Journal of Neurology, Neurosurgery and Psychiatry. 1998; 64(1):78-83.
2. Oosterhuis H. Myasthenia gravis. Groningen, Netherlands: Groningen Neurological Press; 1997.
3. Osserman KE, Genkins G. Studies in myasthenia gravis: review of twenty-year experience in over 1,200 patients. Mt Sinai J Med. 1971; 38:497-537.
4. Engel AG. Acquired autoimmune myasthenia gravis. En: Engel AG, Franzini-Amstrong C, editors. Myology. New York: Mc-Graw-Hill; 1994.
5. Jaretzki A 3rd, Barohn RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. 2000; 55:16–23.
6. Ferri FF. Ferri’s clinical advisor: Instant diagnosis and treatment. St. Louis, MO: Mosby; 2003.
7. Foulks MCJ. Myasthenia gravis presenting as laryngeal stridor after exposure to chlorine gas. South Med J. 1981; 74:1423-24.
8. Schmidt-NowaraWW, Marder EJ, Feil PA. Respiratory failure in myasthenia gravis due to vocal cord paresis. Arch Neurol. 1984; 41:567-68.
9. Marlowe FI, D’Angelo AJ. Respiratory failure as the initial presentation of myasthenia gravis. Ear Nose Throat J. 1989; 68:472-73.
10. Bhat S1, Gupta D, Chokroverty S. Sleep Disorders in Neuromuscular Diseases. Neurol Clin. 2012; 30:1359–1387.
11. Quera-Salva MA, Guilleminault C, Chevret S, Troche G, Fromageot C, Crowe McCann C, et al. Breathing disorders during sleep in myasthenia gravis. Ann. Neurol. 1992; 31:86-92.
12. Shintani S, Shiozawa Z, Shindo K, Matsui T, Tsunoda S. Sleep apnea in well-controlled myasthenia gravis. Rinsho Shinkeigaku. 1989; 29(5):547-553.
13. Punjabi NM. The epidemiology of adult obstructive sleep apnea. Proc Am Thorac Soc. 2008 Feb 15; 5(2):136-143.
14. Tufik S, Santos-Silva R, Taddei JA, Bittencourt LR. Obstructive sleep apnea syndrome in the Sao Paulo Epidemiologic Sleep Study. Sleep Med. 2010 May; 11(5):441-6.
15. Gold AR, Schwartz AR. The pharyngeal critical pressure. The whys and hows of using nasal continuous positive airway pressure diagnostically. Chest. 1996; 110(4):1077-1088.
16. Fogel RB, Malhotra A, White DP. Sleep. 2: pathophysiology of obstructive sleep apnoea/hypopnoea syndrome. Thorax. 2004; 59(2):159-163.
17. Bradley TD, Brown IG, Grossman RF, Zamel N, Martinez D, Phillipson EA, et al. Pharyngeal size in snorers, nonsnorers, and patients with obstructive sleep apnea. N Engl J Med. 1986; 315(21):1327-1331.
18. Schwab RJ, Gefter WB, Hoffman EA, Gupta KB, Pack AI. Dynamic upper airway imaging during awake respiration in normal subjects and patients with sleep disordered breathing. Am Rev Respir Dis. 1993; 148(5):1385-1400.
19. Anch AM, Remmers JE, Sauerland EK, Degroot WJ. Oropharyngeal patency during walking and sleep in the Pickwickian syndrome: electromyographic activity of the tensor veli palatini. Electromyogr Clin Neurophysiol. 1981; 21(2-3):317-330.
20. Jeffries B, Brouillette RT, Hunt CE. Electromyographic study of some accessory muscles of respiration in children with obstructive sleep apnea. Am Rev Respir Dis. 1984; 129(5):696-702.
21. Brennick MJ, Pack AI, Ko K, Kim E, Pickup S, Maislin G, et al. Altered upper airway and soft tissue structures in the New Zealand Obese mouse. Am J Respir Crit Care Med. 2009; 179(2):158-169.
22. Amino A, Shiozawa Z, Nagasaka T, Shindo K, Ohashi K, Tsunoda S, et al. Sleep apnoea in well-controlled myasthenia gravis and the effect of thymectomy. J Neurol. 1998; 245: 77–80.
23. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991 Dec; 14(6):540-545.
24. Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med. 1999 Oct 5; 131(7):485-491.
25. Lipp MEN, Guevara AJH. Validação empírica do Inventário de Sintomas de Stress. Estudos de Psicologia. 1994; 11(3), 43-49.
26. Rossetti MO, Ehlers DM, Guntert IB, Leme IFAS, Rabelo ISA, Tosi SMVD, Pacanaro V, Barrionuevo VL. Lipp’s inventory of symptoms of stress for adults (ISSL) in federal civil servants of São Paulo. Rev. bras. ter. cogn. 2008; 4(2):108-119.
27. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun; 67(6):361- 70.
28. Herrmann C. International experiences with the Hospital Anxiety and Depression Scale—a review of validation data and clinical results. J Psychosom Res. 1997; 42(1):17-41.
29. Johnston M, Pollard B, Hennesseyet P. Construct validation of the hospital anxiety and depression scale with clinical populations. Journal of Psychosomatic Research. 2000; 48:579-584.
30. Botega NJ, Bio MR, Zomignani MA, Garcia C, Pereira WA. Mood disorders among inpatients in ambulatory and validation of the anxiety and depression scale HAD. Rev Saude Publica. 1995; 29(5):355-63.
31. Lacson E Jr, Xu J, Lin SF, Dean SG, Lazarus JM, Hakin RM. A comparison of SF-36 and SF-12 composite scores and subsequent hospitalization and mortality risks in long-term dialysis patients. Clin J Am Soc Nephrol. 2010; 5(2):252–260.
32. Ciconelli RM, Ferraz MB, Santos W, Meinão I, Quaresma MR. Tradução para a língua portuguesa e validação de questionário genérico de avaliação de qualidade de vida SF-36 (Brasil SF-36). Rev Bras de Reumatol. 1999; 39(3):143–150.
33. Burns TM, Grouse CK, Conaway MR, Sanders DB and the MG composite and the MG-QOL15 study group. Construct and concurrent validation of the MG-QOF15 in the practice settings. Muscle Nerve. 2010; 41:219-226.
34. Mourao AM, Araujo CM, Barbosa LSM, Gomez RS, Burns TM, Lemos SMA, et al. Brazilian cross-cultural translation and adaptation of the “Questionnaire of Life Quality Specific for Myasthenia Gravis - 15 items”. Arq. Neuro- Psiquiatr. 2013 Dec; 71(12):955-958.
35. Burns TM, Conaway MR, Cutter GR, Sanders DB and the muscle study group. Construction of an efficient evaluative instrument for myasthenia gravis: The MG composite. Muscle Nerve. 2008; 38:1553-1562.
36. Burns TM, Conaway MR, Sanders DB, on behalf oh the MG composite and MG-QOF15 Study Group. The MG Composite: A valid and reliable outcome measure for myasthenia gravis. Neurology. 2010; 74:1434-1440.
37. Burns TM. The MG composite: an outcome measure for myasthenia gravis for use in clinical trials and everyday practice. Ann. N.Y. Acad. Sci. 2012; 1274:99–106.
38. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan W. Reliability testing of the Quantitative Myasthenia Gravis Score. Ann. N.Y. Acad. Sci. 1998 May 13; 841:769-772.
39. Barnett C, Katzberg H, Navabi M, Bril V. The Quantitative Myasthenia Gravis Score: Comparison With Clinical, Electrophysiological, and Laboratory Markers. J Clin Neuromuscul Dis. 2012; 13(4):201-205.
40. Barnett TC, Bril V, Davis AM. Performance of individual items of the quantitative myasthenia gravis score. Neuromuscular Disorders. 2013; 23;413-417.
41. WHO: Obesity: preventing and managing the global epidemic. Report of a WHO Consultation. In WHO Technical Report Series 894. Geneva World Health Organization; 2000.
42. Brodsky L: Modern assessment of tonsils and adenoids. Pediatr Clin North Am. 1989; 36(6):1551-1569.
43. Mallampati SR, Gatt SP, Gugino LD, Desai SP, Waraksa B, Freiberger D, et al. A clinical sign to predict difficult tracheal intubation: a prospective study. Can Anaesth Soc J. 1985; 32(4):429-434.
44. Gabrielsen AM, Lund MB, Kongerud J, Viken KE, Roislien J, Hjelmesaeth J. The relationship between anthropometric measures, blood gases and ling function in morbidly obese white subjects. Obes Surg. 2011; 21:485-491.
45. Miller M, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005; 26:319–338.
46. Pereira CAC. II Consenso Brasileiro de Espirometria. J Pneumol. 2002; 28(supl3):S1-S82.
47. Pellegrino R, Viegi G, Brusasco V, Crapo R, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948–968.
48. Hankinson J, Odencrantz J, Fedan K. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med. 1999; 159:179–187.
49. Fabbri L, Pauwels R, Hurd S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary updated 2003. COPD. 2004; 1:105–141.
50. Magnani KL, Cataneo AJM. Respiratory muscle strength in obese individuals and influence of upper-body fat distribution. Med J. 2007; 125(4):215-219.
51. Neder JA, Andreoni S, Lerario MC, Nery LE. Reference values for lung function tests. II. Maximal respiratory pressures and voluntary ventilation. Braz J Med Biol Res. 1999; 32:719-27.
52. Ambrosino N, Opasich C, Crotti P, Cobelli F, Tavazzi L, Rampulla C. Breathing pattern, ventilatory drive and respiratory muscle strenght in patients with chronic heart failure. Eur Respir J. 1994; 7:17-22.
53. Rechtschaffen A, Kales A. A manual of standardized terminology: techniques and scoring system for sleep stages of human subjects. In Psychiatry and Clinical Neurosciences. Volume 55. Los Angeles: Brain Information Service/ Brain Research Institute. 1968; 2001:305-310.
54. American Academy of Sleep Medicine. The AASM Manual for the scoring of sleep and associated events. Rules, terminology and technical specifications; 2007.
55. Logan AG, Perlikowski SM, Mente A, Tisler A, Tkacova R, Niroumand M, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens. 2001; 19(12):2271-2277.
56. Otake K, Delaive K, Walld R, Manfreda J, Kryger MH. Cardiovascular medication use in patients with undiagnosed obstructive sleep apnoea. Thorax. 2002; 57(5):417-422.
57. Yeh J, Chen W, Chiu H, Lee C, Hsu C. Plasmapheresis does not affect polysomnographic parameters in patients with Myasthenia Gravis: A case series study. Artificial organs. 2010; 34(6):E200-E203.
58. Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, et al. Association of sleep disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA. 2000; 283(14):1829-1836.
59. Peker Y, Hedner J, Kraiczi H, Loth S. Respiratory disturbance index: an independent predictor of mortality in coronary artery disease. Am J Respir Crit Care Med. 2000; 162(1):81-86.
60. Kim HC, Young T, Matthews CG, Weber SM, Woodward AR, Palta M. Sleep-disordered breathing and neuropsychological deficits. A population-based study. Am J Respir Crit Care Med. 1997; 156(6):1813-1819.
61. Flemons WW, Tsai W. Quality of life consequences of sleep-disordered breathing. J Allergy Clin Immunol. 1997; 99(2):S750-756.